Panacea awaits WHO’s approval: Report

15 Jan 2013 Evaluate

Panacea Biotec, India’s second largest producer of vaccines and a highly progressive research based health management company is reportedly awaiting World Health Organization’s (WHO) approval to resume supplying vaccines for the world immunisation programme from its units at Lalru (Haryana) and Baddi (Himachal Pradesh).

Further towards this development, the company is expecting WHO’s officials to visit its units in Lalru and Baddi for prequalification next month after having recently shifted its Easy five pentavalent vaccine to its new unit in Baddi, which may aid the company in grabbing the next supply deal.

Companies are qualified to bid for WHO tenders to supply drugs only if their vaccines are in the list of prequalified vaccines. Panacea manufactured the five-in-one vaccine, used to treat diphtheria, pertussis, tetanus, haemophilus influenza B and hepatitis B in children, at its unit in Delhi and the raw material at the Lalru unit.

However, in mid-2011, WHO delisted the Lalru unit, citing irregularities and deficiencies in the plant’s quality management system. As a result, three of the company’s diptheria-pertussis-tetanus-based combination vaccines, Easyfive, Ecovac4 and EnivacHB, were also delisted from WHO’s list of pre-qualified vaccines. Additionally, back in March 2012, Panacea had voluntarily withdrawn its oral polio vaccine, or OPV, (also produced at the company’s Delhi facility) from WHO’s list of pre-qualified vaccines, reasoning the manufacturing unit needed corrective action.

Panacea Biotec Share Price

451.80 15.35 (3.52%)
11-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1687.55
Dr. Reddys Lab 1109.15
Cipla 1463.15
Lupin 1969.05
Zydus Lifesciences 868.25
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...